Federal Circuit Upholds Patent Protections for Janssen, Blocking Mylan’s Generic Invega Trinza

The United States Court of Appeals for the Federal Circuit has reaffirmed a lower court’s ruling in favor of Janssen Pharmaceuticals Inc., maintaining the company’s patent protection against Mylan Laboratories Ltd.’s attempt to introduce a generic version of the schizophrenia medication Invega Trinza. On Friday, the court dismissed Mylan’s appeal, which contended that the generic drug’s production would lead to patent infringement due to the dosing regimen used by healthcare providers. This decision effectively prevents Mylan from moving forward with its plans to release a generic form of the drug. Further details on the case can be accessed through Law360.